- Home
- NTIP vs GBIO Comparison
NTIP vs GBIO Comparison
Compare NTIP & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- GBIO
- Stock Information
- Founded
- NTIP 1990
- GBIO 2016
- Country
- NTIP United States
- GBIO United States
- Employees
- NTIP N/A
- GBIO N/A
- Industry
- NTIP Multi-Sector Companies
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- GBIO Health Care
- Exchange
- NTIP Nasdaq
- GBIO Nasdaq
- Market Cap
- NTIP 28.6M
- GBIO 29.2M
- IPO Year
- NTIP 1998
- GBIO 2020
- Fundamental
- Price
- NTIP $1.25
- GBIO $0.35
- Analyst Decision
- NTIP
- GBIO Strong Buy
- Analyst Count
- NTIP 0
- GBIO 4
- Target Price
- NTIP N/A
- GBIO $7.33
- AVG Volume (30 Days)
- NTIP 13.9K
- GBIO 1.1M
- Earning Date
- NTIP 08-11-2025
- GBIO 08-06-2025
- Dividend Yield
- NTIP 8.00%
- GBIO N/A
- EPS Growth
- NTIP N/A
- GBIO N/A
- EPS
- NTIP N/A
- GBIO N/A
- Revenue
- NTIP $250,000.00
- GBIO $24,556,000.00
- Revenue This Year
- NTIP N/A
- GBIO N/A
- Revenue Next Year
- NTIP N/A
- GBIO N/A
- P/E Ratio
- NTIP N/A
- GBIO N/A
- Revenue Growth
- NTIP N/A
- GBIO 146.47
- 52 Week Low
- NTIP $1.16
- GBIO $0.30
- 52 Week High
- NTIP $1.78
- GBIO $3.65
- Technical
- Relative Strength Index (RSI)
- NTIP 51.66
- GBIO 45.19
- Support Level
- NTIP $1.21
- GBIO $0.31
- Resistance Level
- NTIP $1.30
- GBIO $0.37
- Average True Range (ATR)
- NTIP 0.05
- GBIO 0.03
- MACD
- NTIP -0.00
- GBIO -0.00
- Stochastic Oscillator
- NTIP 64.29
- GBIO 39.09
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.